Pharmaceutical Executive: May 2026

View the Pharmaceutical Executive May 2026 issue in an interactive format.

The takeaway leadership message from our May issue is clear: Future progress will come from those willing to rethink the machinery — not just the medicine.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

Trialynx’s CEO discusses the benefits of using AI for trial design and how to find the AI companies doing the most promising work.

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more efficient.

Agentic AI is reshaping pharma market entry by enabling real-time, data-driven insights that allow companies to ask more complex strategic questions and act faster — with greater precision.

It’s also about knowing when you’re stuck and need a reset.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Mindsets must shift from increasing headcount to prioritizing competency-based training and systems.